AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study

Back

HFA Premium Access

AZD3427, a relaxin mimetic in pulmonary hypertension group 2 associated with left heart disease: design and rationale of the phase 2b Re-PHIRE Study

Session: ePosters in chronic heart failure - treatment 5

Topic: Pharmacotherapy

Speaker: Professor M. Ufnal (Gothenburg, SE)

Event: Heart Failure 2024

Congress Presentation

Add to my library

About the speaker

Professor Marcin Ufnal

AstraZeneca, Gothenburg (Sweden)

0 follower

5 more presentations in this session

The impact of modifiable risk factors on readmissions during the vulnerable period in patients with heart failure

Speaker: Assistant Professor A. Lacraru (Bucharest, RO)

Effect of intravenous FCM therapy on myocardial work indices in patients with HFrEF and ID.

Speaker: Professor A. Safarova (Baku, AZ)

Prospective evaluation of sacubitril/valsartan utilization patterns and clinical outcomes in Korean patients with heart failure with reduced ejection fraction: real-world post-marketing surveillance

Speaker: Professor J. Choi (Seoul, KR)

ARNi treatment in adults with Tetralogy of Fallot: a single-centre experience

Speaker: Doctor A. Ferreira (Lisbon, PT)

Effect of guideline-recommended medical therapy according to blood urea nitrogen

Speaker: Doctor P. Tolomeo (Glasgow, GB)

Access the full session

ePosters in chronic heart failure - treatment 5

Speakers: Professor M. Ufnal, Assistant Professor A. Lacraru, Professor A. Safarova, Professor J. Choi, Doctor A. Ferreira...

Access

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources